Sugi Predict

Sugi Predict / Compounds / SCHEMBL56379

SCHEMBL56379

SCHEMBL56379

CC(C)(C)OC(=O)N1CCN(S(C)(=O)=O)CC1

nearest known ligand 0.53

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ GPR119 Q8TDV5 2/20 0.48
▸ TGM2 P21980 9/20 0.47
▸ F13A1 P00488 6/20 0.47
▸ TGM1 P22735 3/20 0.47
▸ STS P08842 1/20 0.46
▸ HTT P42858 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ HPGD P15428 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL189729 0.93 MEN1 (0.49) USP2SMN1; SMN2GPR119TGM2F13A1
SCHEMBL7406478 0.85 USP2 (0.53) USP2SMN1; SMN2GPR119TGM2F13A1
SCHEMBL1487081 0.85 USP2 (0.53) USP2SMN1; SMN2GPR119TGM2F13A1
SCHEMBL310402 0.85 ALDH1A1 (0.51) USP2SMN1; SMN2GPR119HPGD
SCHEMBL698803 0.84 USP2 (0.69) USP2SMN1; SMN2GPR119HTTHPGD
SCHEMBL18294 0.84 USP2 (0.69) USP2SMN1; SMN2GPR119HTTHPGD
SCHEMBL2249760 0.84 USP2 (0.51) USP2SMN1; SMN2TGM2F13A1TGM1
SCHEMBL23487527 0.83 USP2 (0.47) USP2SMN1; SMN2GPR119TGM2F13A1
SCHEMBL6957235 0.82 ALDH1A1 (0.46) USP2SMN1; SMN2GPR119HPGD
SCHEMBL22567334 0.82 GPR119 (0.59) SMN1; SMN2GPR119HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12616753-B2 HSP70 inhibitors and methods of using same THE WISTAR INSTITUTE (US) 2026-05-05 — — US disclosed
US-20250145628-A1 PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF NOVO NORDISK A/S (DK) 2025-05-08 — — US disclosed
CN-119301126-A Pyrazolopyrimidine compound, composition containing pyrazolopyrimidine compound and application of pyrazolopyrimidine compound 诺和诺德股份有限公司 2025-01-10 — — CN disclosed
EP-4479402-A1 PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF Novo Nordisk A/S (DK) 2024-12-25 — — EP disclosed
US-20240116872-A1 PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING GENENTECH, INC. (US) 2024-04-11 — — US disclosed
WO-2023155004-A1 PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF INVERSAGO PHARMA INC. (CA) 2023-08-24 — — WO disclosed
US-20230265054-A1 PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING GENENTECH, INC. (US) 2023-08-24 — — US disclosed
WO-2023139536-A1 (4-PIPERAZIN-1YL)-4-ALKYL-PHTHALAZIN-1(2H)-ONE COMPOUNDS AS PARP7 INHIBITORS RHIZEN PHARMACEUTICALS AG (CH) 2023-07-27 — — WO disclosed
US-20230183237-A1 COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 VANDERBILT UNIVERSITY 2023-06-15 — — US disclosed
US-11660303-B2 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity KANCERA AB (SE) 2023-05-30 — — US disclosed
EP-0986551-A1 SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE Takeda Pharmaceutical Company Limited (JP) 2000-03-22 — — EP disclosed
US-5968923-A ANTIINFLAMMATORY AGENTS, TREATMENT OF NERVOUS SYSTEM DISORDERS, GASTROINTESTINAL DISORDERS PFIZER INC. (US) 1999-10-19 — — US disclosed
WO-1998054164-A1 SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-12-03 — — WO disclosed
CN-1154699-A (Azetidin-1-ylalkyl) lactams as tachykinin antagonists PFIZER LTD (IE) 1997-07-16 — — CN disclosed
EP-0775132-A1 (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS Pfizer Limited (GB) 1997-05-28 — — EP disclosed
US-5561140-A IMMUNOSUPPRESSANTS; SIDE EFFECT REDUCTION ABBOTT LABORATORIES (US) 1996-10-01 — — US disclosed
US-5530119-A IMMUNOSUPPRESSANTS ABBOTT LABORATORIES (US) 1996-06-25 — — US disclosed
WO-1996005193-A1 (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS PFIZER LIMITED (GB) 1996-02-22 — — WO disclosed
EP-0690713-A1 SUBSTITUTED ALICYCLIC AMINE-CONTAINING MACROCYCLIC IMMUNOMODULATORS ABBOTT LABORATORIES (US) 1996-01-10 — — EP disclosed
WO-1994021254-A1 SUBSTITUTED ALICYCLIC AMINE-CONTAINING MACROCYCLIC IMMUNOMODULATORS ABBOTT LABORATORIES (US) 1994-09-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145628-A1 PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF CNR1, CNR2, TRPV1 USP2 4098/4885SMN1; SMN2 2594/4885GPR119 48/4885
US-20230265054-A1 PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING SHH, GLI1, SMO USP2 2645/4885SMN1; SMN2 4094/4885GPR119 639/4885
US-20240116872-A1 PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING SHH, GLI1, SMO USP2 2486/4885SMN1; SMN2 4106/4885GPR119 695/4885
US-20230183237-A1 COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 CHRM5, CHRM1, CHRM2 USP2 2706/4885SMN1; SMN2 3044/4885GPR119 187/4885
US-12616753-B2 HSP70 inhibitors and methods of using same HSPB1, HSP90AB1, HSF1 USP2 1942/4885SMN1; SMN2 2284/4885GPR119 3504/4885
US-11660303-B2 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity ROR1, RORB, RORA USP2 4095/4885SMN1; SMN2 1506/4885GPR119 1110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.